CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

By Sukriti Gupta and Purvi Agarwal (Reuters) -European shares started the week on a positive note on Monday after the United ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

Novo Nordisk stock slumped early Monday as the drugmaker was facing a potential hit to revenue from several different ...

In secondary endpoints, 64.6% of participants using Zepbound saw 15% weight loss compared with 40.1% on Wegovy. And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), ...

Lilly's study showed that more patients treated with Zepbound had reductions in body weight of at least 10%, 15%, 20%, and 25% than those treated with Wegovy, while they also achieved a greater ...